Skip to main content

TNF inhibitor

      Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients. EULAR this year proposed new fertility data, especially in Rheumatoid Arthritis, along with an update of the EULAR points to consider for use of antirheumatic drugs in reproduction, pregnancy and lactation.
      RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH

      Peter Nash drpnash

      1 year ago
      RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024
      EULAR Abstract Archive

      OP0031 (2024)
      COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITI

      Peter Nash drpnash

      1 year ago
      EULAR Abstract Archive OP0031 (2024) COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITIS: CARDIOVASCULAR OUTCOMES signif absolute risk diff 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i https://t.co/fNIiMt4caL. @RheumNow #EULAR2024
      Points to consider in pregnancy in
      #rheumatic diseases

      3 points

      ✅TNFi all OK 👍

      ? Only if you can’t control

      Janet Pope Janetbirdope

      1 year ago
      Points to consider in pregnancy in #rheumatic diseases 3 points ✅TNFi all OK 👍 ? Only if you can’t control disease use other #bDMARDs Baby #vaccinations if exposed to #biologics while present #rotovirus ok other live vaccines >6 mos #EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh
      500+ pts AxSPA
      No difference in drug discontinuation between IL-17i, TNFi, IL23i over time
      Adjusted for CRP, co-medicati

      Aurelie Najm AurelieRheumo

      1 year ago
      500+ pts AxSPA No difference in drug discontinuation between IL-17i, TNFi, IL23i over time Adjusted for CRP, co-medication w/ MTX + classic covariates IL-17i and IL-23i had experienced a higher number bDMARD failures #EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
      Cohort from Netherlands 400+ PsA pts IR first bioDMARD
      300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi
      3year rete

      Aurelie Najm AurelieRheumo

      1 year ago
      Cohort from Netherlands 400+ PsA pts IR first bioDMARD 300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi 3year retention rates 12 mo 75% cyclers 80% swappers 24mo 60% cyclers 56% swappers No difference in treatment failure or DAS28 CRP #EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG
      #opportunistic inf in #autoimmune dz
      🎤 @khyrich
      👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺?

      Artem Minalyan, MD, DABOM AMinalyan

      1 year ago
      #opportunistic inf in #autoimmune dz 🎤 @khyrich 👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸) 👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6 👉 🙅‍♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️ 🔗#eular 2022 guide: https://t.co/PIpGpTrH28 #eular2024 #rheumx @RheumNow https://t.co/kouXvradiC
      Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17

      Dr. Antoni Chan synovialjoints

      1 year ago
      Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A
      ×